This study was conducted to investigate the drug-drug interaction of medical cannabis with antidepressant drug groups by using the in silico method. In our study, drug-drug interactions of medical cannabis and antidepressant drug groups were analyzed on the Way2Drug and PubChem web platforms by using their isomeric structures. It was found that selective serotonin reuptake inhibitors (SSRIs) usually posed a minimal risk or showed no interaction; they caused adverse effects when used together with cannabidiol (CBD) and tetrahydrocannabinol (THC), minimum bet occurred when monoamine oxidase (MAO) inhibitors were used with CBD, adverse effects were observed when they were used with THC, and that the use of trazodone, milnacipran, agomelatine, vilazodone, and desvenlafaxine, which are among other antidepressants, with both molecules resulted in adverse effects.